BRAF and melanoma: Inhibition of the activated MAPK pathway through BRAF silencing with RNA interference results in apoptosis of melanoma cell lines carrying the BRAFV600E mutation [8], [9], [10] and regression of BRAFV600E melanoma xenografts [11], suggesting that BRAF is an attractive drug target.